A Critical Analysis of the COMPASS Trial With Respect to Benefit-Risk Assessment Using the Numbers Needed to Treat: Applicability and Relevance in Indian Patients With Stable Cardiovascular Disease

Indian Heart J. Nov-Dec 2018;70(6):911-914. doi: 10.1016/j.ihj.2018.06.006. Epub 2018 Aug 22.

Abstract

The recently published Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial evaluated the hypothesis that rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary prevention. In India, stable cardiovascular disease occurs in a much younger age group relative to the rest of the world. Our critical analysis of COMPASS trial showed that the younger age group appeared to derive greater benefit from the rivaroxaban+aspirin combination (relative to aspirin alone) as seen with number needed to treat metrics as compared to the older age group.

Keywords: Likelihood of being helped and harmed; Rivaroxaban; Stable Coronary artery disease; Young Indian Population.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / prevention & control*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • India / epidemiology
  • Morbidity / trends
  • Numbers Needed To Treat
  • Risk Assessment*
  • Secondary Prevention / methods*
  • Thrombolytic Therapy / methods*

Substances

  • Fibrinolytic Agents